Harangi M - Search Results

1

Afamin Levels and Their Correlation with Oxidative and Lipid Parameters in Non-diabetic, Obese Patients.

Juhász I, Ujfalusi S, Seres I, Lőrincz H, Varga VE, Paragh G Jr, Somodi S, Harangi M, Paragh G. Juhász I, et al. Among authors: harangi m. Biomolecules. 2022 Jan 12;12(1):116. doi: 10.3390/biom12010116. Biomolecules. 2022. PMID: 35053264 Free PMC article.

2

Serum paraoxonase activity changes in uremic and kidney-transplanted patients.

Paragh G, Asztalos L, Seres I, Balogh Z, Löcsey L, Kárpáti I, Mátyus J, Katona E, Harangi M, Kakuk G. Paragh G, et al. Among authors: harangi m. Nephron. 1999;83(2):126-31. doi: 10.1159/000045489. Nephron. 1999. PMID: 10516491 Clinical Trial.

3

[The role of HDL in the prevention of cardiovascular events].

Paragh G, Harangi M. Paragh G, et al. Among authors: harangi m. Orv Hetil. 2001 Jan 21;142(3):121-6. Orv Hetil. 2001. PMID: 11217160 Review. Hungarian.

4

Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?

Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. Balogh Z, et al. Among authors: harangi m. Diabetes Metab. 2001 Nov;27(5 Pt 1):604-10. Diabetes Metab. 2001. PMID: 11694861 Clinical Trial.

5

Determination of DNA damage induced by oxidative stress in hyperlipidemic patients.

Harangi M, Remenyik E E, Seres I, Varga Z, Katona E, Paragh G. Harangi M, et al. Mutat Res. 2002 Jan 15;513(1-2):17-25. doi: 10.1016/s1383-5718(01)00285-6. Mutat Res. 2002. PMID: 11719086

6

[Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment].

Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, Winkler G, Paragh G. Audikovszky M, et al. Among authors: harangi m. Orv Hetil. 2001 Dec 16;142(50):2779-83. Orv Hetil. 2001. PMID: 11820148 Clinical Trial. Hungarian.

7

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.

Paragh G, Seres I, Harangi M, Balogh Z, Illyés L, Boda J, Szilvássy Z, Kovács P. Paragh G, et al. Among authors: harangi m. Diabetes Metab. 2003 Dec;29(6):613-8. doi: 10.1016/s1262-3636(07)70077-0. Diabetes Metab. 2003. PMID: 14707891

8

Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.

Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P. Paragh G, et al. Among authors: harangi m. Curr Med Res Opin. 2004 Aug;20(8):1321-7. doi: 10.1185/030079904125004394. Curr Med Res Opin. 2004. PMID: 15324535 Clinical Trial.

9

Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.

Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, Remenyik E. Harangi M, et al. Eur J Clin Pharmacol. 2004 Dec;60(10):685-91. doi: 10.1007/s00228-004-0820-6. Epub 2004 Oct 14. Eur J Clin Pharmacol. 2004. PMID: 15490140 Clinical Trial.

10

Effect of hyperlipidemia on QT dispersion in patients without ischemic heart disease.

Szabó Z, Harangi M, Lörincz I, Seres I, Katona E, Karányi Z, Paragh G. Szabó Z, et al. Among authors: harangi m. Can J Cardiol. 2005 Aug;21(10):847-50. Can J Cardiol. 2005. PMID: 16107907

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters